1.
Dobre E-G, Voi M, Orlandi E, Martinis C de, Constantin C, Zipeto D, et al. Investigating RUNX2 KO in B16 melanoma cells as a potential strategy to enhance in vivo tumor response to therapeutic approaches. SEE J Immunol [Internet]. 2025 Mar. 25 [cited 2026 Nov. 17];8(CITIM):065. Available from: https://seejim.eu/index.php/seejim/article/view/6121